Kymera Therapeutics, Inc. · NASDAQ:KYMR
Kymera Therapeutics — Q2 2025 Earnings Presentation
18 slides from Kymera Therapeutics's earnings presentation, Aug 11, 2025
Slide 1: Kymera Therapeutics Second Quarter 2025 Quarterly Results Call
Kymera Therapeutics Second Quarter 2025 Quarterly Results Call August 11, 2025
Slide 2: Agenda
Agenda Introduction Bruce Jacobs, CFA, MBA, Chief Financial Officer Key Highlights and Business Update Nello Mainolfi, PhD, Founder, President and Chief Executive Officer Clinical Update Jared Gollob, MD, Chief Medical Officer Financial Review Bruce Jacobs, CFA, MBA, Chief Financial Officer Question
Slide 3: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. These statements include, but are not limited to, implied and express statements about our strategy, business
Slide 4: Clear Vision and History of Strong Execution
Clear Vision and History of Strong Execution VISION EXECUTION IMPACT • Reinventing the treatment of human • Delivered 5 new investigational • Dosed >400 healthy volunteers/patients to disease as a fully integrated degrader drugs into the clinic date across clinical pipeline commercial global biotech
Slide 5: Immunology: A Large, Underserved Market
Immunology: A Large, Underserved Market Oral Degraders with Biologics-Like Profile Can Disrupt the Immunology Market Biologics can have several limitations, making orals preferred by most patients • 160M Total Patients Across Key • Expensive, challenging to prescribe/reimburse Immunologic Diseases1
Slide 6: Building a Best-In-Industry Oral Immunology Pipeline
Building a Best-In-Industry Oral Immunology Pipeline Potential Upcoming 2025 1H 2026 Indications Milestones Immunology - Wholly-Owned Oral Small Molecule Degraders Biomarkers in blood & skin lesions, 28-day efficacy AD, Asthma, Ph2b AD STAT6 COPD, PN, Ph1b AD Data: 4Q25 CRSwNP, EoE, Ph1 HV Ph1b AD P
Slide 7: Phase 1 Healthy Volunteer Exceeded Study Objectives
Phase 1 Healthy Volunteer Exceeded Study Objectives Clinical Data Continues to Support a Dupilumab-like Profile KT-621 Healthy Volunteer KT-621 Healthy Volunteer Endpoint Objectives Data STAT6 Degradation in Blood 90%+ Complete STAT6 Degradation in Skin 90%+ Complete Well tolerated 16-fold above the
Slide 8: KT-621: Phase 1a SAD and MAD Healthy Volunteer Trial
KT-621: Phase 1a SAD and MAD Healthy Volunteer Trial Randomized, Double-blind, Placebo-controlled SAD and MAD in 118 Healthy Volunteers Part A Part B Single Ascending Dose Multiple Ascending Dose Primary (SAD) (MAD) • Safety & tolerability of 14x daily doses escalating single and 800 mg 200 mg multi
Slide 9: Single Dose KT-621 Achieved >90% STAT6 Degradation in Blood
Single Dose Administration of KT-621 Achieved >90% STAT6 Degradation in Blood Across All Dose Levels >95% Mean STAT6 Degradation Achieved at Doses of 75 mg or Greater 20 Placebo Mean (±SE) Percent Change from Baseline in STAT6 6.25 mg SD 0 25 mg SD -20 75 mg SD -40 200 mg SD 400 mg SD -60 800 mg SD
Slide 10: Multiple Daily Doses of KT-621 Achieved Complete STAT6 Degradation
Multiple Daily Doses of KT-621 Achieved Complete STAT6 Degradation in Blood and Skin Mean Absolute STAT6 Levels in Blood1 Mean Absolute STAT6 Levels in Skin2 Placebo n=18 0.3 Placebo n=17 1.5 mg QD n=9 1.5 mg QD n=7 12.5 mg QD n=7 12.5 mg QD n=7 1.0 25 mg QD n=9 25 mg QD n=8 Mean (±SE) STAT6 Mean (±
Slide 11: Robust Inhibition of TARC and Eotaxin-3 Biomarkers
Robust Inhibition of TARC and Eoxtain-3 Biomarkers, Comparable/Superior to Published Dupilumab Data Median Percent Change from Median Percent Change from Baseline in Serum TARC1 Baseline in Serum Eotaxin-32 Percent Change from Baseline in Eotaxin-3 Placebo n=18 Percent Change from Baseline in TARC 2
Slide 12: Healthy Volunteer SAD/MAD Safety Summary
Healthy Volunteer SAD/MAD Safety Summary KT-621 Well Tolerated Across All Doses Evaluated Undifferentiated from Placebo TRAEs by Preferred Term: SAD Cohort • No SAEs SAD 1-6: SAD 1-6: AE Term (severity) PBO KT-621 • No Severe AEs (n=12) (n=36) • No dose dependent pattern in the TEAEs Headache (mild)
Slide 13: KT-621: BroADen Phase 1b Trial
KT-621: BroADen Phase 1b Trial Single Arm, Open Label in Atopic Dermatitis Patients • Single arm, open label 4Q 2025 Design • ~20 patients Adult, Moderate to Phase 1b AD • Daily dose for 28 days; Severe AD Patients 14-day safety follow-up Patient Data Baseline entry criteria: EASI ≥ 16; Dosing • Two
Slide 14: KT-621 Development Plan Enables Efficient Path to Registration Across All Th2 Diseases
KT-621 Development Plan Enables Efficient Path to Registration Across All Th2 Diseases Initial Parallel Phase 2b Trials in Moderate/Severe Atopic Dermatitis (AD) and Asthma are Expected to Support Subsequent Phase 3 Trials Across Multiple Dermatology, GI and Respiratory Indications Ph2b AD Ph3 AD, D
Slide 15: KT-579: Potential First-in-Class Oral Small Molecule Degrader
KT-579: Potential First-in-Class Oral Small Molecule Degrader • IRF5 has the potential to • Human and mouse • IRF5 degradation in vivo • KT-579 fully KT-579 is be the first broad anti- genetics de-risk safety leads to robust cytokine degrades IRF5 a first-in-class, inflammatory to affect and clinica
Slide 16: 2Q 2025 Income Statement
2Q 2025 Income Statement Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024 Collaboration revenue $ 11,476 $ 25,650 $ 33,576 $ 35,937 Operating expenses: Research and development $ 78,388 $ 59,202 $ 158,643 $ 108,021 General and administrative 17,645 17,373 33,916 31,747 Impai
Slide 17: Kymera Collaborations: Key Financial Terms
Kymera Collaborations: Key Financial Terms Gilead: CDK2 Molecular Glue Sanofi: IRAK4 Degrader • Eligible for up to $750 million in total • KT-485 expected to advance into payments Phase 1 in 2026 • Includes $85 million upfront and • Potential to earn up to $975 million in potential option exercise p
Slide 18: Thank You Q&A
Thank You Q&A To ask a question, raise your virtual hand